rapid
diagnost
vaccin
therapeut
import
intervent
manag
novel
coronaviru
outbreak
time
systemat
review
potenti
intervent
includ
middl
east
respiratori
syndromecoronaviru
merscov
sever
acut
respiratori
syndrom
sar
cov
guid
policymak
global
priorit
resourc
research
develop
systemat
search
carri
three
major
electron
databas
pubm
embas
cochran
librari
identifi
publish
studi
accord
prefer
report
item
systemat
review
metaanalys
prisma
guidelin
supplementari
strategi
googl
search
person
commun
use
total
studi
fulfil
criteria
review
sever
laboratori
protocol
confirm
suspect
case
use
realtim
revers
transcript
polymeras
chain
reaction
rtpcr
publish
commerci
rtpcr
kit
develop
beij
genom
institut
current
wide
use
china
like
asia
howev
serolog
assay
well
pointofcar
test
kit
develop
like
near
futur
sever
vaccin
candid
pipelin
like
earliest
phase
vaccin
trial
synthet
dnabas
candid
number
novel
compound
well
therapeut
licens
condit
appear
vitro
efficaci
test
clinic
trial
merscov
sarscov
other
list
clinic
trial
howev
current
effect
specif
antivir
drug
combin
support
highlevel
evid
sinc
middecemb
earli
februari
novel
coronaviru
origin
wuhan
hubei
provinc
china
infect
laboratoryconfirm
case
across
countri
death
casefat
rate
case
death
china
base
initi
report
surg
case
wuhan
major
male
median
age
year
link
huanan
seafood
wholesal
market
report
case
similar
symptom
onset
ill
fever
cough
myalgia
fatigu
case
develop
pneumonia
sever
even
fatal
respiratori
diseas
acut
respiratori
distress
syndrom
novel
coronaviru
betacoronaviru
form
clade
within
subgenu
sarbecoviru
orthocoronavirina
subfamili
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
also
betacoronavirus
zoonot
origin
link
potenti
fatal
ill
outbreak
respect
base
current
evid
pathogen
significantli
lower
sarscov
merscov
howev
potenti
higher
transmiss
r
sarscov
r
merscov
r
possibl
expans
global
declar
outbreak
public
health
emerg
intern
concern
world
health
organ
urgent
need
rapid
diagnost
vaccin
therapeut
detect
prevent
contain
promptli
howev
current
lack
understand
avail
earli
phase
outbreak
systemat
review
describ
assess
potenti
rapid
diagnost
vaccin
therapeut
base
part
develop
merscov
sarscov
systemat
search
carri
three
major
electron
databas
pubm
embas
cochran
librari
identifi
publish
studi
examin
diagnosi
therapeut
drug
vaccin
sever
acut
respiratori
syndrom
sar
middl
east
respiratori
syndrom
mer
novel
coronaviru
accord
prefer
report
item
systemat
review
metaanalys
prisma
guidelin
two
independ
review
focus
sar
mer
respect
third
independ
review
engag
resolv
conflict
articl
interest
use
key
word
sar
coronaviru
mer
novel
coronaviru
wuhan
viru
identifi
diseas
search
strategi
systemat
search
diagnosi
therapeut
drug
vaccin
carri
independ
key
word
drug
therapi
vaccin
diagnosi
point
care
test
rapid
diagnost
test
use
conjunct
diseas
key
word
respect
search
exampl
search
string
found
tabl
search
random
control
trial
rct
valid
trial
diagnost
test
publish
english
measur
sensit
andor
specif
rapid
diagnost
test
pointofcar
test
kit
b
impact
drug
therapi
c
vaccin
efficaci
either
diseas
date
restrict
appli
search
vitro
anim
human
studi
publish
english
decemb
februari
outcom
interest
addit
review
refer
retriev
articl
order
identifi
addit
studi
report
retriev
initi
search
studi
examin
mechan
diagnost
test
drug
therapi
vaccin
efficaci
sar
mer
exclud
googl
search
diagnost
februari
tabl
yield
five
webpag
link
govern
intern
bodi
offici
inform
guidelin
europ
cdc
us
cdc
us
fda
three
webpag
link
diagnost
protocol
scientif
commentari
five
webpag
link
market
news
press
releas
six
protocol
diagnost
use
revers
transcriptas
polymeras
chain
reaction
rtpcr
six
countri
publish
websit
googl
search
vaccin
yield
relev
articl
emerg
real
time
rtpcr
remain
primari
mean
diagnos
new
viru
strain
among
mani
diagnost
platform
avail
tabl
among
diagnost
studi
select
one
studi
discuss
use
rtpcr
diagnos
patient
tabl
period
type
specimen
collect
rtpcr
play
import
role
diagnosi
found
respiratori
specimen
posit
viru
serum
neg
earli
period
also
suggest
earli
day
ill
patient
high
level
viru
despit
mild
symptom
apart
commonli
use
rtpcr
diagnos
merscov
four
studi
identifi
variou
diagnost
method
revers
transcript
loopmedi
isotherm
amplif
rtlamp
rtinsul
isotherm
pcr
rtiipcr
onestep
rrtpcr
assay
base
specif
taqman
probe
rtlamp
similar
sensit
real
time
rtpcr
also
highli
specif
use
detect
merscov
compar
usual
diagnost
test
rapid
simpl
conveni
likewis
rtiipcr
onestep
rrtpcr
assay
also
shown
similar
sensit
high
specif
mercov
lastli
one
studi
focus
valid
six
commerci
real
rtpcr
kit
high
accuraci
although
real
time
rtpcr
primari
method
diagnos
merscov
high
level
pcr
inhibit
may
hinder
pcr
sensit
tabl
eleven
studi
focu
sarscov
diagnost
test
tabl
paper
describ
diagnost
method
detect
viru
major
use
molecular
test
diagnosi
comparison
molecular
test
ie
rtpcr
serolog
test
ie
elisa
show
molecular
test
better
sensit
specif
henc
enhanc
current
molecular
test
conduct
improv
diagnosi
studi
look
use
nest
pcr
includ
preamplif
step
incorpor
n
gene
addit
sensit
molecular
marker
improv
sensit
tabl
addit
seven
potenti
rapid
diagnost
kit
januari
tabl
avail
market
six
research
purpos
one
kit
beij
genom
institut
bgi
approv
use
clinic
set
rapid
diagnosi
kit
rtpcr
two
kit
bgi
china
veredu
singapor
capabl
detect
multipl
pathogen
use
sequenc
microarray
technolog
respect
limit
detect
enhanc
realtim
pcr
method
fold
higher
standard
realtim
pcr
assay
fold
higher
convent
pcr
method
clinic
aspect
enhanc
realtim
pcr
method
abl
detect
case
sarscov
posit
sampl
confirm
assay
sarscov
detect
sampl
sar
patient
day
day
ill
none
sampl
healthi
control
real
time
pcr
threshold
sensit
genom
equival
per
reaction
good
reproduc
interassay
coeffici
variat
specimen
patient
posit
viral
load
rang
genom
equivalentsml
realtim
rtpcr
reaction
sensit
nest
pcr
reaction
detect
limit
nest
pcr
reaction
genom
equival
standard
cdna
control
realtim
reversetranscript
pcr
rrtpcr
rnadepend
rna
polymeras
rdrp
open
read
frame
loopmedi
isotherm
amplif
lamp
enzymelink
immunosorb
assay
elisa
immunofluoresc
assay
ifa
immunochromatograph
test
ict
nasopharyng
aspir
npa
emerg
potenti
vaccin
candid
pipelin
global
tabl
wide
rang
technolog
messeng
rna
dnabas
nanoparticl
synthet
modifi
viruslik
particl
appli
like
take
year
candid
start
phase
clinic
trial
except
fund
coalit
epidem
prepared
innov
cepi
howev
kit
develop
bgi
pass
emerg
approv
procedur
nation
medic
product
administr
current
use
clinic
surveil
center
china
total
uniqu
studi
sar
cov
merscov
vaccin
screen
four
eventu
includ
review
studi
sar
mer
vaccin
exclud
perform
cell
anim
model
figur
four
studi
includ
review
phase
clinic
trial
sar
mer
vaccin
tabl
studi
popul
type
cell
anim
human
point
screen
publish
clinic
trial
mostli
done
unit
state
except
one
sar
vaccin
done
china
vaccin
candid
sar
mer
report
safe
welltoler
abl
trigger
relev
appropri
immun
respons
particip
addit
highlight
six
ongo
phase
clinic
trial
identifi
clinicaltrialsgov
regist
tabl
trial
test
safeti
immunogen
respect
merscov
vaccin
candid
exclud
result
publish
yet
trial
project
complet
decemb
two
studi
russia
decemb
germani
exist
literatur
search
return
result
complet
trial
time
write
among
trial
found
systemat
review
tabl
nine
clinic
trial
regist
clinic
trial
registri
clinicaltrialsgov
therapeut
five
studi
hydroxychloroquin
lopinavir
plu
ritonavir
arbidol
mesenchym
stem
cell
tradit
chines
medicin
glucocorticoid
therapi
usag
commenc
recruit
remain
four
studi
encompass
investig
antivir
interferon
atom
darunavir
cobicistat
arbidol
remdesivir
usag
patient
tabl
seroconvers
measur
occur
particip
dose
respect
maintain
particip
studi
end
week
neutralis
antibodi
detect
particip
one
time
point
studi
maintain
neutralis
activ
end
studi
tcell
respons
detect
particip
dose
respect
differ
immun
respons
dose
group
week
vaccineinduc
humor
cellular
respons
respect
detect
particip
week
molecul
develop
univers
scientist
inhibit
two
coronaviru
enzym
prevent
replic
discov
drug
target
said
similar
enzym
target
found
sar
viru
research
note
identifi
drug
may
avail
address
ongo
outbreak
hope
make
access
futur
outbreak
first
affili
hospit
guangzhou
medic
univers
xue
bi
jing
tcm
approv
recruit
subject
start
besid
six
complet
random
control
trial
rct
select
systemat
review
tabl
one
ongo
random
control
trial
target
sar
therapeut
studi
found
clinicaltrialsgov
updat
sinc
mani
prospect
retrospect
cohort
studi
conduct
epidem
center
usag
ribavirin
lopinavirritonavir
ribavirin
yet
welldesign
clinic
trial
investig
usag
three
complet
random
control
trial
conduct
sar
china
taiwan
hong
kong
studi
respect
investig
antibiot
usag
involv
particip
combin
western
chines
treatment
vs
chines
treatment
particip
integr
chines
western
treatment
patient
usag
specif
chines
medicin
four
particip
earli
use
corticosteroid
particip
anoth
notabl
studi
open
nonrandom
studi
investig
ribavirinlopinavirritonavir
usag
particip
one
random
control
trial
investig
integr
western
chines
treatment
sar
epidem
exclud
chines
articl
one
ongo
random
control
trial
target
mer
therapeut
investig
usag
lopinavirritonavir
interferon
beta
likewis
mani
prospect
retrospect
cohort
studi
conduct
epidem
center
usag
ribavirin
lopinavirritonavirribavirin
interferon
convalesc
plasma
usag
date
one
trial
complet
one
phase
clinic
trial
investig
safeti
toler
fulli
human
polyclon
igg
immunoglobulin
found
avail
literatur
trial
conduct
unit
state
demonstr
safe
welltoler
singl
dose
anoth
trial
mer
therapeut
found
clinicaltrialsgova
phase
trial
unit
state
evalu
safeti
toler
pharmacokinet
pk
immunogen
coadminist
merscov
antibodi
howev
particularli
respect
improv
clinic
symptom
elev
qualiti
life
promot
immun
function
recoveri
promot
absorpt
pulmonari
inflamm
reduc
dosag
cortisteroid
shorten
therapeut
cours
treatment
integr
chines
western
medicin
treatment
obviou
superior
compar
use
control
treatment
alon
microneutr
titr
also
correl
level
serum
singl
infus
mgkg
appear
safe
welltoler
healthi
particip
discuss
rapid
diagnost
play
import
role
diseas
outbreak
manag
fast
accur
diagnosi
specif
viral
infect
enabl
prompt
accur
public
health
surveil
prevent
control
measur
local
transmiss
cluster
prevent
delay
isol
laboratoryconfirm
case
close
contact
quarantin
monitor
home
rapid
diagnost
also
facilit
specif
public
health
intervent
closur
highrisk
facil
area
associ
confirm
case
prompt
infect
control
environment
decontamin
laboratori
diagnosi
perform
detect
genet
materi
viru
b
detect
antibodi
neutral
viral
particl
interest
c
detect
viral
epitop
interest
antibodi
serolog
test
cultur
isol
viabl
viru
particl
key
limit
genet
materi
detect
lack
knowledg
presenc
viabl
viru
potenti
crossreact
nonspecif
genet
region
short
timefram
accur
detect
acut
infect
phase
key
limit
serolog
test
need
collect
pair
serum
sampl
acut
convalesc
phase
case
investig
confirm
elimin
potenti
crossreact
nonspecif
antibodi
past
exposur
andor
infect
coronavirus
limit
viru
cultur
isol
long
durat
highli
special
skill
requir
technician
process
sampl
biolog
sampl
taken
also
play
role
sensit
test
sarscov
merscov
specimen
collect
lower
respiratori
tract
sputum
tracheal
aspir
higher
prolong
level
viral
rna
tropism
viru
merscov
viral
load
also
higher
sever
case
longer
viral
shed
compar
mild
case
although
upper
respiratori
tract
specimen
nasopharyng
oropharyng
swab
use
potenti
lower
viral
load
may
higher
risk
falseneg
among
mild
mer
sar
case
like
among
case
exist
practic
detect
genet
materi
coronavirus
sarscov
merscov
includ
revers
transcriptionpolymeras
chain
reaction
rtpcr
b
realtim
rtpcr
rrtpcr
c
revers
transcript
loopmedi
isotherm
amplif
rtlamp
realtim
rtlamp
nucleic
amplif
test
naat
usual
prefer
case
merscov
diagnosi
highest
sensit
earliest
time
point
acut
phase
infect
chines
health
author
recent
post
full
genom
genbank
gisaid
portal
facilit
detect
viru
sever
laboratori
assay
develop
detect
novel
coronaviru
wuhan
highlight
interim
guidanc
ncov
laboratori
test
suspect
case
includ
protocol
countri
thailand
japan
china
first
valid
diagnost
test
design
germani
corman
et
al
initi
design
candid
diagnost
rtpcr
assay
base
sar
sarsrel
coronaviru
suggest
circul
viru
sarslik
upon
releas
sequenc
assay
select
base
match
upon
inspect
sequenc
align
two
assay
use
rna
depend
rna
polymeras
rdrp
gene
e
gene
e
gene
assay
act
firstlin
screen
tool
rdrp
gene
assay
confirmatori
test
assay
highli
sensit
specif
crossreact
coronaviru
also
human
clinic
sampl
contain
respiratori
virus
hong
kong
univers
use
two
monoplex
assay
reactiv
coronavirus
subgenu
sarbecoviru
consist
sarscov
sarslik
coronaviru
viral
rna
extract
sarscov
use
posit
control
suggest
protocol
assum
sar
erad
propos
n
gene
rtpcr
use
screen
assay
assay
act
confirmatori
test
howev
protocol
evalu
panel
control
posit
control
sarscov
rna
synthet
oligonucleotid
posit
control
yet
test
us
cdc
share
protocol
real
time
rtpcr
assay
detect
primer
probe
design
univers
detect
sarslik
coronaviru
specif
detect
howev
protocol
valid
platform
chemistri
apart
protocol
describ
limit
assay
analyst
engag
train
familiar
test
procedur
result
interpret
fals
neg
result
may
occur
due
insuffici
organ
specimen
result
improp
collect
transport
handl
also
rna
virus
may
show
substanti
genet
variabl
could
result
mismatch
primer
probe
target
sequenc
diminish
assay
perform
result
fals
neg
result
pointofcar
test
kit
potenti
minim
limit
highli
priorit
research
develop
next
month
serolog
test
elisa
iift
neutral
test
effect
determin
extent
infect
includ
estim
asymptomat
attack
rate
compar
detect
viral
genom
molecular
method
serolog
test
detect
antibodi
antigen
would
lag
period
antibodi
specif
target
viru
would
normal
appear
day
ill
onset
furthermor
studi
suggest
low
antibodi
titer
second
week
delay
antibodi
product
could
associ
mortal
high
viral
load
henc
serolog
diagnos
like
use
nucleic
amplif
test
naat
avail
access
vaccin
prevent
protect
infect
diseas
occurr
expos
specif
pathogen
interest
especi
vulner
popul
prone
sever
outcom
context
current
outbreak
vaccin
help
control
reduc
diseas
transmiss
creat
herd
immun
addit
protect
healthi
individu
infect
decreas
effect
valu
diseas
nonetheless
social
clinic
econom
hurdl
vaccin
vaccin
programm
includ
willing
public
undergo
vaccin
novel
vaccin
b
side
effect
sever
advers
reaction
vaccin
c
potenti
differ
andor
low
efficaci
vaccin
popul
differ
clinic
trial
popul
access
vaccin
given
popul
includ
cost
avail
vaccin
vaccin
current
develop
none
test
time
write
januari
coalit
epidem
prepared
innov
cepi
announc
fund
vaccin
develop
programm
inovio
univers
queensland
moderna
inc
respect
aim
test
experiment
vaccin
clinic
week
june
vaccin
candid
develop
dna
recombin
mrna
vaccin
platform
organ
base
recent
merscov
outbreak
alreadi
number
vaccin
candid
develop
still
preclin
test
stage
vaccin
develop
includ
viral
vectorbas
vaccin
dna
vaccin
subunit
vaccin
viruslik
particl
vlp
base
vaccin
inactiv
wholeviru
iwv
vaccin
live
attenu
vaccin
latest
find
vaccin
arebas
review
yong
et
al
august
date
report
one
publish
clinic
studi
merscov
vaccin
geneon
life
scienc
inovio
pharmaceut
one
sar
vaccin
trial
conduct
us
nation
institut
allergi
infecti
diseas
phase
clinic
trial
report
posit
result
one
announc
plan
proceed
phase
trial
due
close
genet
related
sarscov
may
potenti
crossprotect
effect
use
safe
sarscov
vaccin
await
vaccin
howev
would
requir
small
scale
phasebyphas
implement
close
monitor
vaccine
larg
scale
implement
apart
time
diagnosi
case
achiev
favor
clinic
outcom
depend
time
treatment
administ
report
cell
entri
receptor
use
infect
human
sarscov
henc
clinic
similar
two
virus
expect
particularli
sever
case
addit
die
merscov
sarscov
advanc
age
underli
health
condit
hypertens
diabet
cardiovascular
diseas
compromis
immun
system
coronavirus
errorpron
rnadepend
rna
polymeras
rdrp
result
frequent
mutat
recombin
event
result
quasispeci
divers
close
associ
adapt
evolut
capac
enhanc
viralcel
entri
caus
diseas
time
specif
popul
atrisk
sinc
abundantli
present
human
epithelia
lung
small
intestin
coronavirus
like
infect
upper
respiratori
gastrointestin
tract
may
influenc
type
therapeut
similarli
sarcov
howev
year
follow
two
major
coronaviru
outbreak
sarscov
merscov
remain
consensu
optim
therapi
either
diseas
welldesign
clinic
trial
provid
gold
standard
assess
therapeut
measur
scarc
coronaviru
proteas
inhibitor
success
complet
preclin
develop
program
despit
larg
effort
explor
sarscov
inhibitor
bulk
potenti
therapeut
strategi
remain
experiment
phase
hand
cross
vitro
hurdl
stronger
effort
requir
research
treatment
option
major
coronavirus
given
pandem
potenti
effect
treatment
option
essenti
maxim
restor
affect
popul
good
health
follow
infect
clinic
trial
commenc
china
identifi
effect
treatment
base
treatment
evid
sar
mer
current
effect
specif
antivir
highlevel
evid
specif
antivir
therapi
provid
context
clinic
studytri
treatment
shown
real
cur
action
sar
mer
literatur
gener
describ
isol
case
small
case
seri
mani
interferon
three
class
test
antivir
activ
sarscov
vitro
anim
model
interferon
consist
shown
activ
follow
interferon
use
corticosteroid
interferon
synthet
interferon
appear
improv
oxygen
faster
resolut
chest
radiograph
abnorm
observ
studi
untreat
control
interferon
use
multipl
observ
studi
treat
sarscov
merscov
patient
interferon
without
ribavirin
lopinavirritonavir
like
benefici
trial
china
drug
treatment
appear
advanc
time
treatment
like
import
factor
effect
combin
ribavirin
lopinavirritonavir
use
postexposur
prophylaxi
health
care
worker
may
reduc
risk
infect
ribavirin
alon
unlik
substanti
antivir
activ
clinic
use
dosag
henc
ribavirin
without
corticosteroid
lopinavir
ritonavir
among
combin
employ
common
agent
report
avail
literatur
efficaci
assess
observ
studi
retrospect
case
seri
retrospect
cohort
studi
prospect
observ
studi
prospect
cohort
studi
random
control
trial
rang
seven
particip
lopinavirritonavir
kaletra
earliest
proteas
inhibitor
combin
introduc
treatment
sarscov
efficaci
document
sever
studi
caus
notabl
lower
incid
advers
outcom
ribavirin
alon
combin
usag
ribavirin
also
associ
lower
incid
acut
respiratori
distress
syndrom
nosocomi
infect
death
amongst
favor
outcom
recent
vitro
studi
shown
anoth
hiv
proteas
inhibitor
nelfinavir
antivir
capac
sarscov
although
yet
show
favor
outcom
anim
studi
remdesivir
gilead
scienc
nucleosid
analogu
vitro
vivo
data
support
develop
potenti
pancoronaviru
antivir
base
result
sever
coronavirus
cov
includ
highli
pathogen
cov
potenti
emerg
batcov
use
remdesivir
may
good
candid
investig
treatment
improv
mortal
follow
receipt
convalesc
plasma
variou
dose
consist
report
sever
observ
studi
involv
case
sever
acut
respiratori
infect
sari
viral
etiolog
signific
reduct
pool
odd
mortal
follow
treatment
compar
placebo
therapi
observ
studi
howev
moder
high
risk
bia
given
small
sampl
size
alloc
treatment
base
physician
discret
avail
plasma
factor
like
concomit
treatment
may
also
confound
result
associ
convalesc
plasma
hospit
length
stay
viral
antibodi
level
viral
load
respect
similarli
inconsist
across
avail
literatur
convalesc
plasma
promis
like
yet
feasibl
given
limit
pool
potenti
donor
issu
scalabl
monoclon
antibodi
treatment
progress
sarscov
enter
host
cell
bind
spike
protein
angiotensin
convert
enzym
human
monoclon
antibodi
protein
shown
significantli
reduc
sever
lung
patholog
nonhuman
primat
follow
merscov
infect
neutral
antibodi
elicit
activ
passiv
immun
use
vaccin
convalesc
plasma
respect
neutral
antibodi
theoret
harvest
individu
immun
vaccin
uncertainti
achiev
therapeut
level
antibodi
therapeut
agent
also
report
known
antimalari
agent
chloroquin
elicit
antivir
effect
multipl
virus
includ
hiv
type
hepat
b
chloroquin
also
immunomodulatori
capabl
suppress
product
releas
factor
mediat
inflammatori
complic
viral
diseas
tumor
necrosi
factor
interleukin
postul
chloroquin
work
alter
glycosyl
endosom
ph
antiinflammatori
properti
may
benefici
treatment
sar
niclosamid
known
drug
use
antihelminth
treatment
efficaci
niclosamid
inhibitor
viru
replic
proven
sever
assay
immunoblot
analysi
immunofluoresc
assay
niclosamid
treatment
observ
complet
inhibit
viral
antigen
synthesi
reduct
viru
yield
infect
cell
dose
depend
niclosamid
like
interfer
earli
stage
viru
attach
entri
cell
function
proteas
inhibitor
mechan
niclosamid
activ
warrant
investig
glycyrrhizin
also
reportedli
inhibit
viru
adsorpt
penetr
earli
step
viru
replic
glycyrrhizin
significantli
potent
inhibitor
low
select
index
test
sever
pathogen
flavivirus
preliminari
result
suggest
product
nitrou
oxid
inhibit
viru
replic
induct
nitrou
oxid
synthas
mechan
glycyrrhizin
sarscov
remain
unclear
compound
also
rel
lower
toxic
compar
proteas
inhibitor
like
ribavirin
inhibitori
activ
also
detect
baicalin
extract
anoth
herb
use
treatment
sar
china
hong
kong
find
compound
limit
vitro
studi
due
rapidli
evolv
situat
potenti
limit
systemat
review
systemat
review
like
public
bia
develop
yet
report
develop
intent
report
publicli
scientif
platform
due
confidenti
concern
howev
may
limit
develop
review
public
help
brand
extent
compani
andor
funder
furthermor
due
rapid
need
share
statu
develop
may
report
bia
detail
provid
author
scientif
articl
commentari
articl
tradit
media
lastli
viabl
form
qualiti
assess
metaanalysi
select
articl
due
limit
data
provid
heterogen
style
report
differ
articl
paper
provid
comprehens
overview
potenti
develop
pharmaceut
intervent
earli
phase
outbreak
systemat
review
would
use
crosscheck
qualiti
assess
metaanalysi
develop
perform
followup
studi
rapid
diagnost
vaccin
therapeut
key
pharmaceut
intervent
limit
transmiss
respiratori
infecti
diseas
mani
potenti
develop
pharmaceut
intervent
ongo
contain
phase
outbreak
potenti
due
better
pandem
prepared
howev
lesson
merscov
sarscov
shown
journey
develop
still
challeng
move
ahead
supplementari
materi
follow
avail
onlin
http
tabl
exampl
full
search
strategi
pubm
tabl
googl
search
diagnost
tabl
summari
diagnost
assay
develop
tabl
